Corporation (Nasdaq:CHIR) and Cubist Pharmaceuticals Inc. (Nasdaq:CBST) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), has issued a positive opinion recommending approval of Chiron's Marketing Authorization Application (MAA) for CUBICIN(R) (daptomycin). CUBICIN is an IV antibiotic being evaluated by the EMEA for the treatment of complicated skin and soft-tissue infections (cSSTI) caused by Gram-positive bacteria. The CHMP recommendation for approval is an important step toward bringing this novel antibiotic to the European market. Chiron licensed development and commercialization rights to CUBICIN in the EU from Cubist, which launched CUBICIN in the United States in November 2003.
